Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares OutstandingShares Outstanding
Ratios

Medifast (MED) EBIAT (2016 - 2025)

Medifast's EBIAT history spans 16 years, with the latest figure at -$18.1 million for Q4 2025.

  • For Q4 2025, EBIAT fell 2362.05% year-over-year to -$18.1 million; the TTM value through Dec 2025 reached -$18.7 million, down 992.54%, while the annual FY2025 figure was -$18.7 million, 992.97% down from the prior year.
  • EBIAT reached -$18.1 million in Q4 2025 per MED's latest filing, down from -$2.3 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $47.0 million in Q2 2021 to a low of -$18.1 million in Q4 2025.
  • Average EBIAT over 5 years is $19.5 million, with a median of $24.8 million recorded in 2022.
  • The largest YoY upside for EBIAT was 130.41% in 2025 against a maximum downside of 2362.05% in 2025.
  • A 5-year view of EBIAT shows it stood at $34.0 million in 2021, then dropped by 22.06% to $26.5 million in 2022, then plummeted by 77.24% to $6.0 million in 2023, then plummeted by 86.73% to $801000.0 in 2024, then plummeted by 2362.05% to -$18.1 million in 2025.
  • Per Business Quant, the three most recent readings for MED's EBIAT are -$18.1 million (Q4 2025), -$2.3 million (Q3 2025), and $2.5 million (Q2 2025).